According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on discovering as well as developing little molecule medicine prospects to treat cancer cells. The Company‘s items under different stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Several various other equities research analysts also recently talked about the company. Noble Financial reissued a “purchase” ranking as well as issued a $11.00 price purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “buy” score on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 and also a two-hundred day moving average cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, covering experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse web margin of 8,294.27%. The company had revenue of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. During the same quarter in the previous year, the firm posted ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will upload -1.18 EPS for the existing year.
A number of hedge funds have lately bought and sold shares of ONTX. GSA Resources Partners LLP bought a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Funding Administration LP purchased a new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional capitalists own 13.36% of the firm’s stock.
Concerning Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition and also growth of oncology therapeutics. It concentrates on uncovering and also creating tiny molecule medication candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA
. Get a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).
For more details concerning research offerings from Zacks Investment Research, go to Zacks.com.
This immediate information alert was produced by narrative scientific research technology and also monetary data from Market in order to offer visitors with the fastest and most exact reporting. This story was reviewed by Market’s content team prior to magazine.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?
Prior to you think about Onconova Therapeutics, you’ll want to hear this.
Market keeps an eye on Wall Street’s premier and best carrying out research experts and the stocks they suggest to their clients every day. Market has actually recognized the five stocks that top analysts are quietly whispering to their customers to acquire now before the broader market catches on … and Onconova Therapeutics had not been on the listing.
While Onconova Therapeutics currently has a “Buy” score among experts, premier experts think these five stocks are much better acquires.